Scarica l'app Stockscreener
5.28
1.31%
-0.07
Dopo l'orario di chiusura:
5.36
0.08
+1.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$5.35
Aprire:
$5.25
Volume 24 ore:
37,206
Relative Volume:
0.19
Capitalizzazione di mercato:
$32.67M
Reddito:
$4.71M
Utile/perdita netta:
$-90.32M
Rapporto P/E:
-0.6067
EPS:
-8.7032
Flusso di cassa netto:
$-85.19M
1 W Prestazione:
+0.00%
1M Prestazione:
-1.49%
6M Prestazione:
-49.08%
1 anno Prestazione:
-36.92%
Intervallo 1D:
$5.1578
$5.44
Intervallo di 1 settimana:
$4.98
$5.73
Portata 52W:
$4.80
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.28 | 32.67M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Ripresa | Jefferies | Buy |
| 2025-08-18 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics Inc (ALGS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aligos Therapeutics Inc (ALGS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aligos Therapeutics Inc (ALGS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aligos Therapeutics Inc (ALGS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aligos Therapeutics Inc (ALGS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aligos Therapeutics Inc (ALGS) Institutional Confidence - TradingKey
Aligos Therapeutics Inc (ALGS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aligos Therapeutics Inc (ALGS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aligos Therapeutics Inc (ALGS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aligos Therapeutics (ALGS) Slides 8% – Support Test on the Horizon?Factor Rotation - newsline.com
Aligos Therapeutics Inc (ALGS) Stock Price, Quote, News & History - Benzinga
Lake Street Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Aligos Therapeutics (ALGS) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
How (ALGS) Movements Inform Risk Allocation Models - Stock Traders Daily
Cantor Fitzgerald reiterates Aligos stock Overweight on HBV data By Investing.com - Investing.com Nigeria
Aligos’ ALG-215007 candidate ASO for HDV infection - BioWorld News
Cantor Fitzgerald reiterates Aligos stock Overweight on HBV data - Investing.com
Lake Street Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $45 - Moomoo
ALGS Initiated Coverage by Lake Street -- Price Target Announced at $45 - GuruFocus
Aligos Therapeutics stock initiated at Buy by Lake Street on HBV drug potential - Investing.com South Africa
Aligos Therapeutics (ALGS) Showcases Promising Data at EASL Cong - GuruFocus
Hepatitis B data: 40% on Aligos drug reach HBsAg level used for cure regimens - Stock Titan
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - Investing News Network
Aligos Therapeutics Presents Positive Phase 1 Data for Pevifoscorvir Sodium at EASL Congress 2026, Suggesting Reduced cccDNA Reservoir in Chronic HBV Patients - Quiver Quantitative
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - GlobeNewswire Inc.
ALGS Q1 2026 Earnings: Narrower-Than-Expected Loss as Aligos Therapeutics Advances PipelineRevenue Estimate Trend - newsline.com
Cantor Fitzgerald Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $20 - Moomoo
ALGS Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Lawrence M. Blatt discloses 5.1% stake in Aligos Therapeutics (ALGS) - Stock Titan
Aligos (ALGS) Delivers Q1 2026 Beat — EPS $-2.21 vs $-2.27 ExpectedSocial Trade Signals - Newser
Woodline Partners reports 4.4% stake in Aligos Therapeutics (NASDAQ: ALGS) - Stock Titan
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at EASL Congress 2026 - Quiver Quantitative
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - Weekly Voice
Liver disease drug data: Aligos secures 10 EASL 2026 slots - Stock Titan
TradingKey - TradingKey
What you need to know before buying Aligos (ALGS) (Investor Concern) 2026-05-08Crowd Consensus Signals - newser.com
The operating leverage hidden in Aligos (ALGS) results | Q1 2026: EPS Exceeds ExpectationsTarget Revision - Newser
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat - ChartMill
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Investing News Network
China HBV license adds cash as Aligos (NASDAQ: ALGS) faces going‑concern risk - Stock Titan
Aligos lands FDA Fast Track and a $25M China deal for HBV drug - Stock Titan
Earnings Preview: ALGS to Report Financial Results Post-market on May 07 - Moomoo
How Aligos Therapeutics Inc. (ALGS) Affects Rotational Strategy Timing - Stock Traders Daily
Aligos Therapeutics Inc expected to post a loss of $2.22 a shareEarnings Preview - TradingView
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - The Manila Times
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):